Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Corcept Therapeutics Inc.

Start price
Target price
Perf. (%)
€21.85
12.04.22
-
12.04.23
-9.84%
12.04.23

Novavax Inc.

Start price
Target price
Perf. (%)
€52.93
11.04.22
€40.00
11.04.23
4.10%
03.05.22

Very low/no dividend yield expected
very negative Cash Flow expected
ROE lower than 10% per year
high free float
buy
Affimed N.V.

Start price
Target price
Perf. (%)
€4.75
11.04.22
-
11.04.23
-41.07%
08.06.22

Could be worthwhile Investment >10% per year
Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€2.64
06.04.22
€0.000
06.04.23
-22.00%
18.04.22

Could be worthwhile Investment >10% per year
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€2.64
06.04.22
€1.00
06.04.23
-22.00%
18.04.22

Probably not worthwhile Investment
Decining EBIT margin than peer group
overvalued
Very low/no dividend yield expected
Protalix Biotherapeutics Inc.

Start price
Target price
Perf. (%)
€1.76
04.04.22
€0.000
04.04.23
-33.28%
18.04.22

EBIT decline > 20% expected
Revenue decline > 20% expected
Very low/no dividend yield expected
Sustainability is not important
Protalix Biotherapeutics Inc.

Start price
Target price
Perf. (%)
€1.76
04.04.22
€0.000
04.04.23
-35.27%
02.06.22

Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline > 20% expected
overvalued
buy
Paul Hartmann AG

Start price
Target price
Perf. (%)
€326.00
04.04.22
-
04.04.23
-31.60%
05.04.23

Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€2.28
03.04.22
-
03.04.23
-98.20%
04.04.23

Probably not worthwhile Investment
buy
Axsome Therapeutics Inc

Start price
Target price
Perf. (%)
€40.88
03.04.22
-
03.04.23
39.43%
04.04.23

Could be worthwhile Investment >10% per year
buy
BeiGene Ltd ADR

Start price
Target price
Perf. (%)
€184.00
02.04.22
€200.00
02.04.23
-15.22%
16.04.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
buy
Carmat

Start price
Target price
Perf. (%)
€14.84
30.03.22
€18.00
30.03.23
-17.45%
22.10.22

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.60
30.03.22
-
30.03.23
-55.74%
20.11.22

Could be worthwhile Investment >10% per year
Very valuable balance sheet
buy
Aceragen Inc.

Start price
Target price
Perf. (%)
€8.06
29.03.22
€15.30
29.03.23
-17.24%
30.03.23

Could be worthwhile Investment >10% per year
buy
iRhythm Technologies Inc

Start price
Target price
Perf. (%)
€137.00
29.03.22
-
29.03.23
-16.79%
29.03.23

buy
Evolent Health Inc

Start price
Target price
Perf. (%)
€28.40
29.03.22
-
29.03.23
-0.70%
29.03.23

buy
Reata Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€25.40
28.03.22
-
28.03.23
25.20%
02.04.22

Risky Investment
Palisade Bio Inc.

Start price
Target price
Perf. (%)
€59.50
22.03.22
-
22.03.23
-20.59%
31.03.22

Risky Investment
buy
Agenus Inc.

Start price
Target price
Perf. (%)
€2.54
22.03.22
-
22.03.23
-42.13%
21.05.22

buy
Pacira Pharmaceuticals

Start price
Target price
Perf. (%)
€64.50
22.03.22
-
22.03.23
-43.57%
23.03.23

buy
Voyager Therapeutics Inc

Start price
Target price
Perf. (%)
€7.65
21.03.22
€11.00
21.03.23
-7.01%
22.03.23

Could be worthwhile Investment >10% per year
Higher risks for its business
Bovie Medical Corp

Start price
Target price
Perf. (%)
€6.45
20.03.22
-
20.03.23
-8.53%
28.05.22

Risky Investment
buy
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€21.29
16.03.22
€56.00
16.03.23
149.27%
17.03.23

Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
Kala Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€81.03
15.03.22
-
15.03.23
-14.84%
20.03.22

Could be worthwhile Investment >10% per year
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€20.53
14.03.22
€14.00
14.03.23
3.70%
16.03.22

Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating